UCB (UCBJY) Projected to Post Earnings on Thursday

UCB (OTCMKTS:UCBJY) is expected to be posting its results before the market opens on Thursday, February 26th. Analysts expect UCB to post earnings of $2.98 per share and revenue of $4.9258 billion for the quarter.

UCB Price Performance

Shares of UCBJY opened at $163.16 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.01 and a current ratio of 1.35. The business has a fifty day moving average of $150.02 and a 200 day moving average of $137.12. UCB has a 52-week low of $71.16 and a 52-week high of $168.76.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on UCBJY shares. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Sunday, October 26th. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.